Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2015-11-30
2017-09-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fibrinogen plasma level in CABG
In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
Fibrinogen plasma level
At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
Fibrinogen plasma level in AVR
In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
Fibrinogen plasma level
At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
Fibrinogen plasma level in AAR
In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
Fibrinogen plasma level
At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fibrinogen plasma level
At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed written informed consent
Exclusion Criteria
* Language barrier to understand study purposes (e.g. french as a native language)
* Preoperative low level of plasma fibrinogen (\< 1.75 g/l)
* Preoperative anemia (Hb \< 10g/dl)
* Emergency treatment
* Intake of anticoagulants other than aspirin within 14 days preceding surgery.
* Known coagulation disorder.
* Jehovah's witnesses
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gabor Erdoes, MD
Role: PRINCIPAL_INVESTIGATOR
University of Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Bern
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
193/15
Identifier Type: -
Identifier Source: org_study_id